CORAL SPRINGS, Fla., Oct. 21, 2011 /PRNewswire/ -- Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and 2 mg, the generic version of Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, Inc. Glycopyrrolate tablets are intended for use as adjunctive therapy in the treatment of peptic ulcers.
"We're up to our third approval this year," said Robert Edwards, CEO of Boca Pharmacal. "Each approval – including Glycopyrrolate Tablets – has been consistent with our mission to pursue and provide products to the marketplace that are important to our customers, but may be overlooked by some of the huge multinationals. We're continuing to file new ANDAs, and will keep doing so in our ongoing effort to provide the generic products our customers – and their patients – need."
Boca Pharmacal, Inc.
Since its beginnings in 1998, Boca Pharmacal's mission has been to offer niche items that were overlooked by some of the larger generic companies as affordable alternatives to brand-named products.
Using multiple facilities across the globe, Boca Pharmacal has a broad reach and a reliable vertical structure that allows them to develop products that include tablets and capsules, semi-solids, solutions, and suspensions. They continue to invest in research and development to make sure they're providing their clients with a wide variety of offerings. The Boca Pharmacal product line is marketed to chains, wholesalers, distributors, managed markets and government agencies. Boca Pharmacal is located at 3550 NW 126th Avenue, Coral Springs, Florida, 33065. For more information visit www.bocapharmacal.com.CONTACT:
Jennifer MouraBoca Pharmacal3550 NW 126th AveCoral Springs, FL 33065Phone: (954) 346-8810Email: firstname.lastname@example.org
|SOURCE Boca Pharmacal, Inc.|
Copyright©2010 PR Newswire.
All rights reserved